5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release

Journal of Neurochemistry

Volumn 76, Issue 5, 2001, Pages 1521-1531

  Ichikawa, Junji ^a,b   Ishii, Hideo ^a   Bonaccorso, Stefania ^a   Fowler, Wiley L ^a   O'Laughlin, Ian A ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

5 HT1A receptor; Atypical antipsychotic drugs; D2 receptor; Dopamine release, 5 HT2A receptor; Rat medial prefrontal cortex.

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; NEGATIVE SYNDROME; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SCHIZOPHRENIA; SEROTONIN RELEASE;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; AMPHETAMINES; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CEREBRAL CORTEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; MALE; MICRODIALYSIS; PIPERAZINES; PIRENZEPINE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; RISPERIDONE; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS; SULPIRIDE;

ANIMALIA;

EID: 0035096016     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2001.00154.x     Document Type: Article

References (58)

1. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system
2. 1A receptors mediate opposing responses on membrane excitability in rat association cortex
3. 1A receptor selective ligands, R (+)-8-OH-DPAT and (S)-UH 301, differentially affect the activity of midbrain dopamine neurons
4. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
5. Electrophysiological evidence for a functional interaction between 5-HT1a and 5-HT2a receptors in the rat medial prefrontal cortex: An iontophoretic study
6. 1A receptors
7. Effects of buspirone in seven schizophrenic subjects
8. Radioreceptor binding profile of the atypical antipsychotic olanzapine
9. The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat
10. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats
11. 2 serotonin receptors: Evidence for a lack of selectivity
12. 2A receptor activation enhances dialysis levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats
13. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release
14. An open trial of buspirone added to neuroleptics in schizophrenic patients
15. Risperidone: Regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain
16. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine
17. 2 adrenoceptor blockade
18. Ziprasidone, a new antipsychotic, produces a preferential increase in extracellular dopamine (DA) utilization in the medial prefrontal cortex (mPFC)
19. 1A receptor agonist, potentiated S (-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum
20. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs
21. 1A receptors on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens
22. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens
23. 1A receptor antagonist, to rat brain
24. 1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex
25. Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens
26. 1A receptors and their modulation of the activity of serotonergic and dopaminergic neurons in rats
27. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum
28. M100907, a 5-HT2A receptor antagonist, potentiates haloperidol-induced dopamine (DA) release in the medial prefrontal cortex (mPFC), but inhibits that in the nucleus accumbens (NAC)
29. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5HT2 receptors
30. 1A receptors
31. 1A receptors in guinea pig dentate gyrus
32. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
33. Classification of typical and atypical antipsychotic drugs on the basis of D-1, D-2, and serotonin2 pKi values
34. 1C/2 antagonists as therapeutic agents
35. 1A receptors in vivo
36. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study
37. 35S]GTPγS binding study
38. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors
39. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: Correlation with receptor binding
40. Classification of typical and atypical antipsychotic drugs on the basis of D-1, D-2, and serotonin2 pKi values
41. 1A receptor activation
42. 1A receptor activation contributes to ziprasidone-induced dopamine release in rat prefrontal cortex
43. 1A receptor activation increases in vivo dopamine release in rat prefrontal cortex
44. The regulation of dopamine release from nigrostriatal neurons in conscious rats: The role of somatodendritic autoreceptors
45. Characterization and pharmacological responsiveness of dopamine release recorded by microdialysis in the substantia nigra of conscious rats
46. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
47. Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
48. Interaction of SM-3997 with serotonin receptors in rat brain
49. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors
50. 1A, agonist tandospirone on memory functions in schizophrenia
51. Increase of extracellular dopamine in the prefrontal cortex: A trait of drugs with antidepressant potential?
52. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition
53. BIMG 80, a novel potential antipsychotic drug: Evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex
54. 2 receptor blocking agent, ritanserin, in the rat
55. Enhancement of antipsychotic-like properties of raclopride in rats using the selective serotonin2a receptor antagonist MDL 100,907
56. 2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats
57. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors